Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(6):461-462; doi:10.1093/jnci/dji076
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by de Braud, F.
Right arrow Articles by Pelosi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Braud, F.
Right arrow Articles by Pelosi, G.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non–Small-Cell Lung Cancer

Filippo de Braud, Tommaso De Pas, Lorenzo Spaggiari, Giulia Veronesi, Giuseppe Curigliano, Cristina Noberasco, Giuseppe Pelosi

Affiliations of authors: Divisions of Medical Oncology (FDB, TDP, GC, CN), Pathology (GP), and Thoracic Surgery (LS, GV), European Institute of Oncology, Milan, Italy

Correspondence to: Filippo de Braud, MD, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy (e-mail: Filippo.debraud@ieo.it).

The first 10% of the full text of this article appears below.

We found the study by Cappuzzo et al. (1) to be very interesting, and we congratulate the authors on conducting this important clinical trial, which identified factors that were predictive of response to gefitinib. Cappuzzo et al. (1) designed the trial to assess the possible association between activation of epidermal growth factor receptor . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non–Small-Cell Lung Cancer
Federico Cappuzzo
J Natl Cancer Inst 2005 97: 462-463. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J Natl Cancer Inst MonogrHome page
J. Mouchawar, S. Taplin, L. Ichikawa, W. E. Barlow, A. M. Geiger, S. Weinmann, J. Gilbert, M. M. Manos, and M. U. Yood
Late-Stage Breast Cancer Among Women With Recent Negative Screening Mammography: Do Clinical Encounters Offer Opportunity for Earlier Detection?
J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 39 - 46.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
J. G. Zapka, E. Puleo, S. Taplin, L. I. Solberg, J. Mouchawar, C. Somkin, A. M. Geiger, and M. U. Yood
Breast and Cervical Cancer Screening: Clinicians' Views on Health Plan Guidelines and Implementation Efforts
J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 46 - 54.
[Abstract] [Full Text] [PDF]